
RenovoRx (RNXT) Stock Forecast & Price Target
RenovoRx (RNXT) Analyst Ratings
Bulls say
RenovoRx Inc. achieved a revenue of $422K in Q2, a notable increase from $197K in Q1, indicating positive momentum in its financial performance. The company is projected to experience substantial revenue growth, with expectations of reaching $1.3 million in 2025 and escalating to $4.5 million in 2026. As a clinical-stage biopharmaceutical company, RenovoRx's capacity for generating revenue is expected to improve significantly as it advances its proprietary targeted therapies for cancer treatment.
Bears say
RenovoRx has reported a modest revenue of $0.3 million to $0.4 million, with a net loss consistently at $2.9 million, leading to an earnings per share of $(0.08), which aligns with prior estimates but raises concerns about financial sustainability. The company operates in the challenging field of pancreatic cancer treatment, characterized by a dismal 5-year overall survival rate of 12%, underscoring the severe unmet medical need but also the substantial risks involved. In light of these factors, the continued losses, limited revenue generation, and the high-risk nature of the targeted therapies contribute to a negative outlook for RenovoRx's stock.
This aggregate rating is based on analysts' research of RenovoRx and is not a guaranteed prediction by Public.com or investment advice.
RenovoRx (RNXT) Analyst Forecast & Price Prediction
Start investing in RenovoRx (RNXT)
Order type
Buy in
Order amount
Est. shares
0 shares